The easy availability of diverse vaccines, such as live-attenuated vaccines, adjuvanted inactivated vaccines pandemic influenza vaccines, and seasonal influenza vaccines are expected to boost the U.S. influenza vaccine market growth. Due to significant R&D, the transition from trivalent to quadrivalent vaccination formulations to provide improved protection from flu strains is a prominent factor that is expected to propel the U.S. influenza vaccines market growth during the forecast period.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/1127
For instance, Sanofi received U.S. Food and Drug Administration (FDA) approval in November 2019 for a supplementary Biologics License Application for Fluzone High-Dose Quadrivalent (Influenza Vaccine) for adults of age 65 and older. The U.S. Food and Drug Administration (FDA) had earlier authorized Fluzone High-Dose (Influenza Vaccine) in 2009. Sanofi can now market and distribute quadrivalent influenza vaccines in the U.S. owing to this authorization. The new vaccine will be offered for vaccination schedules and initiatives for influenza season in 2020-2021 influenza season, according to the company.
The U.S. influenza vaccine market is expected to grow due to innovative technologies that will boost influenza vaccine manufacturing and decrease vaccine shortage
To enhance their supply capacity, manufacturers are working on vaccine research with novel methods such as adopting modern recombinant and cell-based vaccine manufacturing technologies. For instance, Protein Science Corp obtained approval from the U.S. FDA for Flubok Trivalent Vaccine in the U.S. in 2013. Flubok is the only influenza vaccine made with recombinant technology and has several advantages, including the ability to make vaccines in a timely and efficient manner without relying on egg supplies and is safe for people with egg allergies. Furthermore, Seqirus in 2016, also obtained U.S. FDA clearance for Flucelvax quadrivalent, which is recommended for people of age 4 and above. Flucevax is a four-strain inactivated seasonal influenza vaccine developed at the U.S. Holly Springs facility with cell culture technology. The vaccine was recommended by the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO) during the 2016 influenza season to help prevent two influenza virus strains, A strain and B strain.
Increasing vaccine production capacity by major players helps in addressing crucial challenges such as inequitable access, and vaccine shortages, thus reducing vaccine costs. For instance, Novartis AG and bioCSL Limited collaborated to create Seqirus Company in 2015, focusing on vigorous vaccine manufacture for pandemic preparation and for contributing to the global control and prevention of influenza. Furthermore, major players in the U.S. influenza vaccines market are expected to invest to develop novel technologies and expand manufacturing capacity, which is expected to propel the influenza vaccine market growth. For instance, the U.S. Department of Health and Human Services (HHS) stated in December 2019 that it has financed US$ 226 million over six years to raise capacity to manufacture recombinant influenza vaccines in the U.S. A public-private partnership among the Biomedical Advanced Research and Development Authority (BARDA), which is part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), and Sanofi Pasteur will commence vaccine production.
Furthermore, significant developments in preparation and production levels by major players in the manufacturing of influenza vaccines are expected to drive the U.S. influenza vaccines market growth. According to the Centers for Disease Control and Prevention (CDC), producers are expected to supply around 162 to 169 million doses of U.S. influenza vaccine market in February 2020, for the 2019-2020 influenza season.
Key Takeaways of the U.S. influenza vaccines market:
- The U.S. influenza vaccines market is expected to grow at 16.1 % CAGR during the forecast period of 2019-2027, due to increasing awareness about immunization to minimize the disease’s significant health burden.
- Among vaccine types, the quadrivalent vaccine segment in 2016, accounted for the largest share in the U.S. influenza vaccines market, due to the vaccine’s increased disease coverage and rising manufacturing capacity, as a result of its efficacy by major companies.
- Among age group, adults’ segment is expected to account for the largest share in the U.S. influenza vaccines market during the forecast period, due to the country’s growing adult population, increased availability, and ease of approval of influenza vaccines recommended for adults.
- Key players operating in the U.S. influenza vaccine market are GlaxoSmithKline Plc., Sanofi Pasteur, Medimmune, and Seqirus Vaccines Limited.
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/1127
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Vaccine Type
- Market Snippet, By Virus Type
- Market Snippet, By Age Group
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Epidemiology
- PEST Analysis
- Key Highlights
- Recommendations for Nasal Spray Vaccines
- Influenza Vaccines Production Technologies
- Influenza Vaccines Approved in U.S., 2017-18 Influenza Season
- Influenza Vaccine Price List
- Supply Capacity of Major Manufacturers
- Market Dynamics
- U.S. Influenza Vaccines Market, By Vaccine Type, 2016–2027, (US$ Billion)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Trivalent Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
- Quadrivalent Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
- Introduction
- U.S. Influenza Vaccines Market, By Virus Type, 2016–2027, (US$ Billion)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Influenza Virus Type A
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
- Influenza Virus Type B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
- Introduction
- U.S. Influenza Vaccines Market, By Age Group, 2016–2027, (US$ Billion)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
- Introduction
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837